The new software was also added to the FDA's Tap Pilot program, an honor reserved for “high-quality, safe, effective and innovative medical devices."

Data from nearly 9.9 million participants were included in the team’s final analysis. The group emphasized the important role governments can play in trying to reverse the world's reliance on these products. 

“It can be a challenging discussion to have with patients because there is evidence that cannabis has some therapeutic properties," one researcher said. "However, as suggested by this study, cannabis use also has significant cardiovascular risks.”  

Interventional cardiologists have been anticipating this news for quite some time. The device, the first of its kind, provides an alternative treatment option to repeat PCI or cardiac surgery for patients with coronary ISR.

The new collaboration is designed to ensure patients who may face an increased risk of heart disease receive the follow-up care they need.

The self-expandable device was designed to treat “no-option” chest pain patients who see no long-term benefits from other interventions. 

The Ornish diet, a plant-based option developed to help prevent heart disease, also made the final ranking. 

The company officially launched its Cleerly ISCHEMIA software for delivering noninvasive evaluations of CCTA exams in early 2024. This update provides a closer look at the software from a billing perspective.